The Dales Report – Optimi Health: Why This Large-Scale Supplier of Psilocybin Is Taking The Natural Route


The Dales Report with Dane Stevens


Based in Princeton, B.C., Optimi Health (CNSX: OPTI | OTCMKTS: OPTHF | FRA: 8BN) is one of a handful of Health Canada-licensed companies focusing on the production of psilocybin, but there are a few things that set it apart from the rest.

Last week, The Dales Report sat down with Optimi’s co-founder, director, and chief marketing officer Dane Stevens to learn more about the newly licensed company and how it plans to differentiate itself from other companies, by becoming the first to produce large quantities of natural psilocybin.

Stevens, who is also the president and director of Vancouver boutique jewelry store Cavalier, became immersed in the industry after having a personal experience with magic mushrooms.

“I had a really positive interaction with them, and it set the stage for the last three years of my life,” he says, noting that the leadership team’s personal history with psychedelics has a lot to do with why Optimi is choosing to focus exclusively on naturally derived psilocybin.

Why Optimi Is Focused On Natural Psilocybin

“We looked at what we were passionate about and our personal history that had got us to that point, and it’s all been natural,” he says. “For thousands of years, people have been using natural psychedelics, and it’s only recently that the synthetics had come aboard. We see that as the biggest opportunity to help people.”

Where a drug development company might take eight to ten years to create a drug appropriate for a prescription model, says Stevens, working with natural psilocybin gives the company an opportunity “to help people today.”

While synthetic and natural psilocybin are identical compounds, Stevens and team are strong believers that if given the choice, most people would opt for the latter, especially given consumer narratives around ‘natural’ products: “Where our culture is at, I think that having something natural is going to get the attention,” he says.

Optimi’s Functional Mushrooms Line

When it comes to product development, Optimi is currently working on a proprietary psilocybin extraction method. It also recently launched a line of ‘functional’ mushrooms supplements, non-psychedelic products containing mushrooms such as Lion’s Mane and Reishi, that are intended to be used daily.

“It’s really important for Optimi to have revenue. I think that’s a key differentiator as well… we don’t want to have to keep going back to our shareholders and asking for more money,” he says. “At the end of the day, we want to be self-sustainable.”

Large-Scale Production In The Works

Optimi has also been named a supplier to Health Canada’s Special Access Program. Magic mushrooms are cultivated in its two 10,000-square-foot facilities, a capacity that is (so far) unmatched by other licensed dealers of psilocybin.

“We’re working with different physicians who will actually be the ones buying this from us, and then administering to patients,” says Stevens. “That’s the next step, and we fit really well into that ecosystem, where, to my knowledge, we are the only large-scale supplier of GMP-grade natural psilocybin mushrooms.”

To learn more about Optimi’s focus on natural psilocybin and its role in the Special Access Program, watch my interview with Dane Stevens.

Source: The Dales Report




Investor Relations
Phone: +1 (902) 880 6121


Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.


Investor Relations
Phone: +1 (902) 880 6121


This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Products do not contain psilocybin

Get news & updates directly to your inbox.
Thank you for your interest in our investor presentation.

Please sign up here and we will send the presentation to your inbox.
Interested In Optimi? Let's Talk.